Buprenorphine Opioid Treatment During the COVID-19 Pandemic—Reply
Open Access
- 1 August 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 181 (8), 1135-1136
- https://doi.org/10.1001/jamainternmed.2021.0774
Abstract
In Reply We thank Luigi et al for their thoughtful comments highlighting the policy context of our study. Continued access to buprenorphine during the COVID-19Keywords
This publication has 5 references indexed in Scilit:
- Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 PandemicJAMA Internal Medicine, 2021
- Insurance Coverage after Job Loss — The Importance of the ACA during the Covid-Associated RecessionThe New England Journal of Medicine, 2020
- Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicineJournal of Substance Abuse Treatment, 2020
- Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related MortalityAnnals of Internal Medicine, 2019
- Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or BuprenorphineHealth Affairs, 2017